World Lung 2024 – Boehringer and Bayer battle over a lung cancer niche
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Bayer changes tack in targeted lung cancer
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.
ASCO 2024 – Enhertu nears its “ultralow” dream
But toxicity could hold back Destiny-Breast06's ability to change clinical practice.
Bolt’s setback didn’t come out of the blue
The company scraps its lead project and clears out its C-suite, but there was already a precedent.
Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
